Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor.

[1]  M Kiessling,et al.  Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastoma , 2007, International journal of cancer.

[2]  O. H. Chan,et al.  Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. , 2000, Journal of medicinal chemistry.

[3]  O. Kallioniemi,et al.  Molecular cytogenetic analysis of 11 new breast cancer cell lines , 1999, British Journal of Cancer.

[4]  P. Harari,et al.  Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. , 1999, Cancer research.

[5]  G. Tortora,et al.  Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  C. Dinney,et al.  Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Schmidt-Ullrich,et al.  The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  H. Gibbs,et al.  Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? , 1999, Seminars in oncology.

[9]  Kuala Lumpur Malaysia,et al.  Expression of c-erbB3 protein in primary breast carcinomas. , 1998, British Journal of Cancer.

[10]  W. Denny,et al.  Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Porter,et al.  Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis , 1998, Oncogene.

[12]  C. Dean,et al.  Two erbB-4 transcripts are expressed in normal breast and in most breast cancers , 1998, Oncogene.

[13]  P. Fisher,et al.  Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells , 1998, Oncogene.

[14]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[15]  B. Kavanagh,et al.  Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation , 1997, Oncogene.

[16]  R. Jove,et al.  Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. , 1997, Cancer research.

[17]  S. Ethier,et al.  erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. , 1996, Cancer research.

[18]  M. Kitajima,et al.  Effect of endogenous and exogenous EGF on the growth of EGF receptor-hyperproducing human squamous cell carcinoma implanted in nude mice. , 1995, British Journal of Cancer.

[19]  R. Baserga,et al.  Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. , 1995, Cancer research.

[20]  N. Rosen,et al.  Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. , 1995, The Journal of clinical investigation.

[21]  R. Baserga.  Oncogenes and the strategy of growth factors , 1994, Cell.

[22]  A. Bridges,et al.  A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. , 1994, Science.

[23]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  V. P. Collins,et al.  Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. , 1994, Oncogene.

[25]  H. Hurst,et al.  Transcriptional regulation of the c-erbB-3 gene in human breast carcinoma cell lines. , 1993, Oncogene.

[26]  B. Weber,et al.  Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. , 1993, Cancer research.

[27]  J. Tilly,et al.  Epidermal growth factor and basic fibroblast growth factor suppress the spontaneous onset of apoptosis in cultured rat ovarian granulosa cells and follicles by a tyrosine kinase-dependent mechanism. , 1992, Molecular endocrinology.

[28]  D. Ruiter,et al.  Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. , 1992, The Journal of investigative dermatology.

[29]  M. Chao.  Growth factor signaling: Where is the specificity? , 1992, Cell.

[30]  D. Neal,et al.  Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. , 1991, British Journal of Cancer.

[31]  J. Farndon,et al.  Synthetic oligonucleotides as therapeutic agents. , 1991, British Journal of Cancer.

[32]  J. Russo,et al.  Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. , 1990, Cancer research.

[33]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[34]  J. Farndon,et al.  EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.

[35]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[36]  T. Fleming,et al.  Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .

[37]  A. Harris,et al.  Epidermal growth factor receptor and other oncogenes as prognostic markers. , 1992, Journal of the National Cancer Institute. Monographs.

[38]  J. Farndon,et al.  Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. , 1989, Journal of steroid biochemistry.